Hrt Financial LP Amicus Therapeutics, Inc. Transaction History

Hrt Financial LP

$15.7 Billion
Q4 2024

A detailed history of Hrt Financial LP transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Hrt Financial LP holds 102,390 shares of FOLD stock, worth $940,964. This represents 0.01% of its overall portfolio holdings.

Number of Shares

102,390

Previous 50,801 101.55%

Holding current value

$940,964

Previous $542,000 77.86%

% of portfolio

0.01%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$9.36 - $12.01 $482,873 - $619,583	51,589 Added 101.55%	102,390 $964,000
Q3 2024 Nov 12, 2024	BUY	$9.55 - $12.09 $485,149 - $614,184	50,801 New	50,801 $542,000
Q1 2023 May 12, 2023	SELL	$10.91 - $13.54 $938,052 - $1.16 Million	-85,981 Reduced 29.58%	204,695 $2.27 Million
Q4 2022 Feb 10, 2023	BUY	$9.89 - $12.7 $2.36 Million - $3.03 Million	238,531 Added 457.44%	290,676 $3.55 Million
Q3 2022 Nov 14, 2022	BUY	$9.82 - $12.75 $512,063 - $664,848	52,145 New	52,145 $544,000
Q4 2021 Feb 14, 2022	SELL	$9.82 - $12.44 $1.59 Million - $2.01 Million	-161,594 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$8.74 - $11.84 $1.41 Million - $1.91 Million	161,594 New	161,594 $1.54 Million
Q4 2020 Feb 16, 2021	SELL	$13.47 - $24.89 $1.32 Million - $2.43 Million	-97,800 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$12.89 - $15.89 $1.26 Million - $1.55 Million	97,800 New	97,800 $1.38 Million
Q4 2019 Feb 14, 2020	SELL	$7.48 - $10.75 $177,059 - $254,463	-23,671 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$8.02 - $13.25 $189,841 - $313,640	23,671 New	23,671 $189,000

Others Institutions Holding FOLD

# of Institutions

312

Shares Held

311M

Call Options Held

467K

Put Options Held

515K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $2.58B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Account